KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Other Working Capital Changes (2016 - 2025)

Pfizer (PFE) has disclosed Other Working Capital Changes for 17 consecutive years, with -$8.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 12.15% to -$8.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.3 billion, a 61.86% increase, with the full-year FY2025 number at -$1.3 billion, up 61.86% from a year prior.
  • Other Working Capital Changes was -$8.2 billion for Q4 2025 at Pfizer, down from $36.0 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $8.1 billion in Q4 2022 to a low of -$10.9 billion in Q4 2021.
  • A 5-year average of -$411.0 million and a median of $1.2 billion in 2021 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: plummeted 1095.01% in 2021, then skyrocketed 654.38% in 2023.
  • Pfizer's Other Working Capital Changes stood at -$10.9 billion in 2021, then soared by 174.36% to $8.1 billion in 2022, then plummeted by 223.24% to -$10.0 billion in 2023, then grew by 5.89% to -$9.4 billion in 2024, then increased by 12.15% to -$8.2 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Other Working Capital Changes are -$8.2 billion (Q4 2025), $36.0 million (Q3 2025), and $5.0 billion (Q2 2025).